The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse)

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 42; no. 2; p. 192
• Main Authors: Bloch, Mark T, Smith, Don E, Quan, Dick, Kaldor, John M, Zaunders, John J, Petoumenos, Kathy, Irvine, Kathy, Law, Matthew, Grey, Pat, Finlayson, Robert J, McFarlane, Robert, Kelleher, Anthony D, Carr, Andrew, Cooper, David A
• Format: Journal Article
• Language: English
• Published: United States 01.06.2006
• Subjects: Adult; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - adverse effects; Anti-HIV Agents - pharmacology; Anti-HIV Agents - therapeutic use; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; HIV - drug effects; HIV Infections - drug therapy; Homosexuality; Humans; Hydroxyurea - administration & dosage; Hydroxyurea - adverse effects; Hydroxyurea - pharmacology; Hydroxyurea - therapeutic use; Male; RNA, Viral - blood; Treatment Outcome; Viral Load
• ISSN: 1525-4135
• DOI: 10.1097/01.qai.0000219779.50668.e6

Structured treatment interruptions (STIs) have been postulated to improve virologic control in primary HIV infection (PHI) by stimulating HIV-specific T-lymphocyte immunity. The addition of hydroxyurea (HU) may reduce viral production from activated CD4 cells. Patients with PHI received a standardized antiretroviral (ARV) regimen consisting of indinavir 800 mg twice daily (BID), ritonavir 100 mg BID, didanosine 400 mg (QD), and either stavudine 40 mg BID or lamivudine 150 mg BID, for up to 12 months and were randomized to HU 500 mg BID or not. If viral suppression (<50 copies/mL) was achieved, up to 3 STIs were undertaken. Two ARV cycles were allowed after each interruption if virologic rebound to more than 5000 RNA copies/mL occurred. Treatment success was defined as maintaining viral loads below 5000 copies/mL for 6 months after ARV interruption. Sixty-eight male homosexual patients were randomized: 35 to ARV + HU and 33 to ARV-alone. Median baseline HIV RNA was 5.73 log10 copies/mL, and median CD4 T-lymphocyte count was 517 cells/microL. Treatment success was not significantly different between those receiving and not receiving HU, with 9 (26%) and 9 (27%), respectively, maintaining viral load at less than 5000 copies/mL in each group (P = 0.88). Virologic control was achieved by 11 (19%) of 59 after 1 STI, 1 (2%) of 41 after 2 STIs, and 6 (17%) of 36 after the third STI. Serious adverse events were recorded for 9 (26%) of 35 of patients using HU and 3 (9%) of 33 in the ARV-only group (P = 0.28). CD4 cell increases were significantly blunted for the HU group compared to the ARV-alone group after the initial treatment phase (+101 cells vs. +196 cells, respectively, P = 0.006). Hydroxyurea was not found to be beneficial when used in association with STIs in patients during PHI.